[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017,67:145-172. [2] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015).中华传染病杂志,2016,34:385-394. [3] Guo T, Chang L, Xiao Y, et al. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015,10:e0122124. [4] Wunsch E, Raszeja-Wyszomirska J, Barbier O, et al. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis, 2018,27:273-279. [5] Kilanczyk E, Banales JM, Wunsch E, et al. S-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes. Biochim Biophys Acta Mol Basis Dis, 2020,1866:165895. [6] Azemoto N, Abe M, Murata Y, et al. Earlybiochemicalresponse to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol, 2009,44:630-634. [7] Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology, 2006,130:715-720. [8] 边新渠,陈杰,刘燕敏,等.熊去氧胆酸治疗原发性胆汁性胆管炎患者血清甲状腺激素水平变化.实用肝脏病杂志,2019,22:716-719. [9] 陈杰,黄春洋,黄云丽,等.大黄利胆胶囊对熊去氧胆酸经治的原发性胆汁性胆管炎患者临床疗效观察.中西医结合肝病杂志,2020,30:492-494. [10] 王建军,赵平. S-腺苷蛋氨酸临床应用研究进展.2011,3:57-60. [11] 郝娟,吕靖,邢枫,等.原发性胆汁性胆管炎的药物治疗进展.临床肝胆病杂志,2020,36:222-226. [12] Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol, 2012,57:1097-1109. |